Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
March 21st, 2008
Neurobiological Technologies, Inc. (NASDAQ:NTII) and the Buck Institute for Age Research (Buck) announced they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's Disease (AD). Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse the symptoms of Alzheimer's disease. AD is a neurodegenerative disease that, in its most common form, occurs in people over 65 years old and is the most common cause of dementia afflicting 24 million people worldwide. AD Research at...
Source: Health Business Week (2008-03-21)
|
